Prolium Bioscience is a clinical stage company developing PRO-203, a potential best-in-class, bispecific CD20xCD3 antibody for severe autoimmune diseases, including systemic sclerosis (SSc) and systemic lupus erythematosus (SLE). Founded and backed by RTW Investments, Prolium has assembled a team wi... Read more
Employees
1-10This company has no teams yet
This company has no offices yet